Keyword: Innovent Biologics
While 2018 was a big year for Chinese R&D on the whole, the sector hit the headlines for the wrong reasons.
The agreement sees Innovent pay $40 million upfront and commit to about $350 million in milestones for a trio of drugs that are in phase 2 and 3.
China’s Junshi Biosciences may follow in Innovent Biologics’ footsteps as it tees up to raise $414 million in its Hong Kong IPO.
Chinese biotech Innovent Biologics is reportedly considering a $200 million IPO later this year that could take place in the U.S.